Please login to the form below

Not currently logged in

UK pharma slams new drug evaluation plans

ABPI London offices

ABPI and BIA oppose "arbitrary" proposal to impose £100,000 QALY limit on rare disease therapies

Merck settles PD-1 patent lawsuit with BMS and Ono

Merck and Co - US headquartersAgrees to pay $625m settlement plus royalties on sales of Keytruda until 2026

Lilly to buy migraine drug developer CoLucid for $960m

Eli Lilly HQDeal revolves around lasmiditan, which the firm out-licensed in 2005

Merck forges cancer-focused big data alliance with Palantir

Merck KGaAPlans to develop a collaborative analytics platform to accelerate research and improve outcomes

Merck pays Vertex $230m upfront for cancer programmes

Merck KGaALicences four DNA damage and repair programmes with first-in-class or best-in-class potential

Shire pays record $350m to settle US kickback allegations

Shire BasingstokeCharges centred around diabetic foot ulcer treatment Dermagraft, which it sold in 2014

Pharma 'getting away with murder', says Trump

US flagAlmost $25bn wiped off big pharma stocks as US President-elect turns attention to drug pricing

Kite bags $90m upfront in two Asian deals for lead CAR-T drug

Partners with Daiichi Sankyo and Fosun Pharma to focus in on non-Hodgkin lymphoma

Lilly streamlines and culls leadership roles

Eli Lilly HQMerges Europe and emerging markets interests and expands diabetes and oncology

Fair to medalling

Generally competent at strategic planning, how can pharma transition from acceptable to exceptional to deliver gold standard performances?

Featured jobs

Subscribe to our email news alerts


Add my company
TVF Communications

At TVF we do things a bit differently – our in-house design and development teams work directly alongside our commercial...

Latest intelligence

Medius Deal Watch
Deal Watch December 2016
Allergan, AZ, BMS, Pfizer, Roche and more feature in this month's pharma deals round-up...
The Young Dementia Network - much more than a logo
Welcome to the second and final part of my two-part blog....
Patient-centred care innovation in dementia: a conversation with Neil Maiden
Content Marketing Manager Liz Inskip interviews Neil Maiden of City, University of London, about his work developing mobile technology solutions for residential dementia care, and what the challenges facing innovators...